UMIN ID: UMIN000040043
Registered date:24/04/2020
A case series study of bevacizumab-associated fistula formation in cervical cancer patients.
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | Advanced or recurrent cervical cancer |
| Date of first enrollment | 2020/04/27 |
| Target sample size | 6 |
| Countries of recruitment | Japan |
| Study type | Others,meta-analysis etc |
| Intervention(s) |
Outcome(s)
| Primary Outcome | Characteristics and prior treatments of patients who developed fistulas after administration of bevacizumab. |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | Not applicable |
|---|---|
| Age maximum | Not applicable |
| Gender | Female |
| Include criteria | |
| Exclude criteria | None |
Related Information
| Primary Sponsor | St. Mary's Hospital and Chugai Pharmaceutical Co., Ltd. |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Chugai Pharmaceutical Co., Ltd. |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Co., Ltd. Chugai Pharmaceutical |
| Address | 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku,Tokyo 103-8324,Japan Japan 103-8324 |
| Telephone | 03-3273-0866 |
| cma-clinicaltrial@chugai-pharm.co.jp | |
| Affiliation | Medical Affairs Div. Medical Science Dept. |
| scientific contact | |
| Name | Toru Sugiyama |
| Address | 422 Tsubukuhonmachi, Kurume,Fukuoka 830-8543,Japan Japan |
| Telephone | 0942-35-3322 |
| to-sugiyama@st-mary-med.or.jp | |
| Affiliation | St. Mary's Hospital Department of Obstetrics and Gynecology |